Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
This 3-part webinar series, hosted by Allen C. Bowling, MD, PhD, director, NeuroHealth Institute, and clinical professor of neurology, University of Colorado, provides participants with evidence-based information about the effects of cannabis on MS symptoms, including pain and spasticity.
Episode 21 of "Mind Moments," a podcast from NeurologyLive, features Indu Subramanian, MD, director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers, who details the results and implications of a recent study that suggests that preventing social isolation—particularly in the time of COVID-19—can help prevent disease worsening.
The director of the Montefiore Einstein Center for the Aging Brain details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.
A recently published critique of aducanumab's trial results calls for a third and definitive phase 3 study of the investigational agent, which is awaiting a decision from the FDA.
Trevor Resnick, MD, a key opinion leader in epilepsy care, discusses how to address nonadherence issues with patients receiving medication for epilepsy, especially adolescents.